Published in Drug Law Weekly, August 21st, 2007
Total product revenues for the quarter were $6.9 million as compared to $6.6 million for the comparable 2006 period. PDT revenues totaled $4.1 million versus $3.8 million for the comparable 2006 period. The increase in PDT revenues was driven primarily by a 19% increase in U.S. Levulan(R) Kerastick(R) revenue. Despite the anticipated impact on Nicomide(R) from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.